Ten-year surveillance of invasive Streptococcus pneumoniae isolates in central Turkey prior to the introduction of a conjugate vaccine

Abstract

Although the seven-valent conjugate vaccine is expected to protect less than half of children younger than three years of age, of the incorporation of this vaccine into the routine immunization program of Turkey is advised to continue. However, the 13-valent conjugate vaccine, including serotypes 1, 3, 5, and 7, has the most potential prevent the highest burden of invasive pneumococcal diseases in this age group.